Liver protection on AAS cycles: what the evidence actually supports

What did @boldenonebilly actually say?

Honestly? Not much. The transcript contains four sentences: "legalize anabolic steroids. Wake me up before you go go. Anabolic swag. Make the voices stop." That is the complete spoken content of this video. The substantive claims about liver health, HDL/LDL production, plaque buildup, arterial stiffness, and clotting risk appear exclusively in the caption, not in anything the creator actually said on camera.

This distinction matters. The caption reads like a real health advisory, warning that liver dysfunction from AAS use shifts lipid profiles toward more LDL and less HDL, which then drives cardiovascular damage. Those are serious, specific physiological claims. But they were never actually spoken or explained in the video itself. Viewers are expected to absorb medical guidance from a text caption attached to what is essentially a meme video.

Does the science back the caption's claims?

The lipid disruption claims in the caption are largely accurate, even if they arrive without any supporting explanation. Anabolic-androgenic steroid use does suppress HDL and elevate LDL, and that shift is associated with accelerated atherosclerotic risk. The mechanism is real and well-documented.

Hartgens and Kuipers (2004, Sports Medicine) conducted a comprehensive review showing that AAS use consistently decreases HDL cholesterol by 20-70% depending on the compound, dose, and duration. Oral 17-alpha alkylated steroids cause the most dramatic lipid suppression. Testosterone esters cause less severe but still clinically meaningful shifts. Baggish et al. (2017, Circulation) used cardiac MRI and CT angiography to demonstrate that long-term AAS users had significantly greater coronary plaque volume and left ventricular dysfunction compared to non-using athletes. The arterial stiffness and oxidative stress claims also have supporting evidence. Kasikcioglu et al. (2007, International Journal of Cardiology) found impaired endothelial function and increased oxidative markers in AAS users. So the cardiovascular cascade described in the caption, from lipid shift to plaque to clotting risk, is physiologically coherent and evidence-supported.

What did they get wrong, or right?

The caption gets the basic lipid-cardiovascular pathway right. Credit where it is due: the claim that reduced HDL combined with elevated LDL drives plaque buildup and arterial stiffness is not broscience. It reflects actual pharmacological risk observed in AAS-using populations.

What is wrong is the framing. The caption implies the liver is the primary driver of cardiovascular risk through lipid dysregulation, but this is an oversimplification. AAS-induced lipid disruption is not purely a liver-mediated event. Androgens act directly on steroidogenic pathways and hepatic lipase activity, but they also affect peripheral lipid metabolism. Attributing the entire cardiovascular risk cascade to liver dysfunction sells the complexity short.

The caption also mentions "all of these" supplements for liver health without naming any of them in either the caption or the transcript. Viewers get a warning about cardiovascular risk with zero actionable, evidence-based guidance. That is a problem. Vague supplement endorsements with no specifics are not health advice. They are content hooks.

The hashtag category lists this as peptide content, but nothing in the video or caption addresses peptides at all. That is a categorization mismatch worth flagging.

What should you actually know?

If you are using AAS, or considering it, the cardiovascular risk is not hypothetical or distant. It is measurable, trackable, and starts accumulating early. Bloodwork showing lipid shifts is not just a number, it is a real-time marker of cardiovascular loading.

Regular lipid panels, including a full fasting lipid panel with LDL particle size if available, are the minimum standard of care. Baggish et al. (2017) found that even relatively young AAS users in their 30s and 40s showed atherosclerotic changes not seen in age-matched non-users. Echo and CT angiography findings in that cohort were sobering. The myocardial fibrosis and reduced left ventricular function they documented do not always come with symptoms until they do, catastrophically.

If you are working with a telehealth provider, liver enzyme panels (AST, ALT, GGT) and lipid monitoring should be scheduled and reviewed, not just ordered and ignored. The liver health conversation in the caption is incomplete without discussing the cardiovascular downstream effects in full, and without naming what interventions actually have evidence behind them rather than gesturing at unnamed supplements.